Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.50 |
| ▸ | F7 | P08709 | 4/20 | 0.47 |
| ▸ | F3 | P13726 | 3/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3846277 | 1.00 | ELANE (0.50) | ELANEF7F3CES2KDM4E | |
| SCHEMBL2317449 | 0.95 | ELANE (0.56) | ELANEF7F3CTRC | |
| SCHEMBL2317459 | 0.95 | ELANE (0.56) | ELANEF7F3CTRC | |
| SCHEMBL2358717 | 0.89 | ELANE (0.49) | ELANEF7F3CES2KDM4E | |
| SCHEMBL2358720 | 0.89 | ELANE (0.49) | ELANEF7F3CES2KDM4E | |
| SCHEMBL12104568 | 0.88 | ELANE (0.61) | ELANEF7F3CTRC | |
| SCHEMBL2213292 | 0.86 | ELANE (0.54) | ELANECES2KDM4EALDH1A1CTRC | |
| SCHEMBL2211272 | 0.86 | ELANE (0.54) | ELANECES2KDM4EALDH1A1CTRC | |
| SCHEMBL3847003 | 0.85 | ELANE (0.46) | ELANECTRC | |
| SCHEMBL2209970 | 0.84 | F7 (0.49) | ELANEF7F3CES2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | ELANE 2303/4885F7 4598/4885F3 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.